By Counterforce Health Team in Vimizim (elosulfase alfa) —

How to Get Vimizim (Elosulfase Alfa) Covered by Humana in New York: Requirements, Appeals, and Timeline

Answer Box: Getting Vimizim Covered by Humana in New York

Who qualifies: Patients with confirmed MPS IVA (Morquio A syndrome) diagnosis through enzyme testing and genetic confirmation. Fastest approval path: Submit prior authorization with specialist attestation, diagnostic test results, and baseline functional measures. Start today: Contact your prescribing specialist to gather enzyme assay results and initiate the PA request through Humana's provider portal. If denied, New York's external appeal process provides binding review within 30 days (72 hours for urgent cases).

Table of Contents

  1. Who Should Use This Guide
  2. Member & Plan Basics
  3. Clinical Criteria for Approval
  4. Required Documentation Package
  5. Submission Process
  6. Common Denial Reasons & Solutions
  7. Appeals Process in New York
  8. Cost Considerations
  9. FAQ
  10. Quick Reference Checklist

Who Should Use This Guide

This guide helps patients with MPS IVA (Morquio A syndrome) and their healthcare providers navigate Humana's prior authorization process for Vimizim (elosulfase alfa) in New York. You'll need this if:

  • You have confirmed MPS IVA diagnosis and your doctor recommends Vimizim
  • Humana is your primary insurance (Medicare Advantage or commercial plans)
  • You're starting treatment or transferring care to New York
  • You've received a denial and need to appeal

Expected outcome: With complete documentation, most approvals are granted within 30 days. Humana's Medicare Advantage denial rate is approximately 3.5%—among the lowest of major insurers—but denials often stem from incomplete documentation rather than medical necessity disputes.

Member & Plan Basics

Coverage Requirements

  • Prior authorization required: Yes, universal requirement for Vimizim across all Humana plans
  • Formulary status: Typically requires prior authorization regardless of tier placement
  • Plan types covered: Medicare Advantage, Medicare Part D, and commercial plans
  • Age restrictions: FDA-approved for patients 5 years and older

Deductible Considerations

For Medicare Advantage members, Vimizim falls under Part B coverage as a provider-administered drug. Commercial plan members should verify whether the drug falls under medical or pharmacy benefits, as this affects deductible application.

Clinical Criteria for Approval

Primary Requirements

Diagnosis Confirmation:

  • Reduced or absent GALNS enzyme activity in cultured blood or skin cells
  • Genetic testing confirming pathogenic mutations in the GALNS gene
  • Clinical presentation consistent with MPS IVA

Prescriber Requirements:

  • Must be a specialist (geneticist, metabolic specialist, or pediatrician experienced with MPS disorders)
  • Specialist attestation and contact information required

Dosing and Administration

  • Standard dose: 2 mg/kg IV infusion weekly
  • Administration: Requires specialty infusion center or hospital outpatient setting
  • Duration: Initial approval typically 6-12 months with reauthorization required

Baseline Testing Requirements

Documentation must include:

  • Urine keratan sulfate (uKS) levels or glycosaminoglycan (GAG) levels
  • Functional assessments: 6-minute walk test, timed 25-foot walk test, or 3-minute stair climb test
  • Pulmonary function tests (maximum voluntary ventilation, forced vital capacity)
Clinician Corner: Medical necessity letters should reference FDA labeling for MPS IVA, include specific enzyme activity results below reference range, and document baseline functional measures. BioMarin provides clinical support resources for healthcare providers managing Vimizim patients.

Required Documentation Package

Essential Documents

  1. Prior authorization form (obtain current version from Humana provider portal)
  2. Specialist attestation letter including:
    • Confirmed MPS IVA diagnosis with enzyme and genetic test results
    • Clinical rationale for treatment
    • Baseline functional assessment results
    • Treatment goals and monitoring plan
  3. Laboratory reports:
    • GALNS enzyme activity assay (must show values below reference range)
    • Genetic testing results confirming pathogenic GALNS variants
    • Baseline biomarker levels (uKS or GAG)
  4. Clinical documentation:
    • Office visit notes documenting MPS IVA symptoms
    • Baseline functional test results
    • Any prior treatment attempts or contraindications

Coding Requirements

  • HCPCS Code: J1322 (injection, elosulfase alfa, 1 mg)
  • ICD-10 Code: E76.219 (Morquio mucopolysaccharidoses, unspecified)
  • Billing units: Based on patient weight (maximum 920 units per 28 days typical)

Submission Process

Step-by-Step Submission

  1. Gather documentation (allow 1-2 weeks for lab reports and specialist letters)
  2. Complete PA form through Humana provider portal or obtain current form
  3. Submit via preferred method:
    • Online: Humana provider portal (fastest processing)
    • Fax: Use number specified on current PA form
    • Mail: Include tracking for paper submissions
  4. Obtain confirmation number and document submission date
  5. Follow up: Check status after 5-7 business days

Expected Timeline

  • Standard review: 30 days from complete submission
  • Expedited review: 72 hours for urgent medical needs
  • Incomplete submissions: May receive request for additional information within 14 days

When patients need coverage assistance navigating complex prior authorization requirements, Counterforce Health helps turn insurance denials into targeted, evidence-backed appeals by analyzing denial letters and plan policies to draft point-by-point rebuttals aligned with each payer's specific requirements.

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
Insufficient diagnostic confirmation Submit complete enzyme and genetic testing GALNS activity assay + genetic report
Missing specialist attestation Obtain letter from qualified specialist Geneticist or metabolic specialist letter
Incomplete baseline measures Provide functional assessments 6-minute walk test, PFTs, biomarkers
Site of care issues Confirm appropriate infusion setting Infusion center or hospital outpatient verification
Dosing/quantity concerns Justify weight-based dosing Patient weight documentation + dosing calculation

Prevention Tips

  • Use only accredited laboratory results for enzyme testing
  • Ensure genetic reports clearly identify pathogenic variants
  • Include all baseline functional measures in initial submission
  • Verify specialist credentials and contact information
  • Double-check HCPCS coding and unit calculations

Appeals Process in New York

Internal Appeals (First Level)

  • Deadline: 60 days from denial notice
  • Timeline: 30 days for standard, 72 hours for expedited
  • Submission: Humana member services or provider portal

External Appeals (New York State)

If internal appeal is unsuccessful, New York offers robust external appeal rights:

  • Eligibility: Available after internal appeal completion
  • Deadline: 4 months from final adverse determination
  • Timeline: 30 days standard, 72 hours expedited (24 hours for urgent drug denials)
  • Cost: $25 fee (waived for Medicaid and financial hardship)
  • Outcome: Binding decision on Humana

Filing External Appeals

  1. Complete application through NY Department of Financial Services (DFS) portal
  2. Include physician attestation for rare disease treatment
  3. Attach supporting documentation (denial letters, medical records, clinical literature)
  4. Submit via DFS online portal or mail as directed
Note: Community Health Advocates provides free assistance with external appeals in New York. Call 888-614-5400 for support with filing appeals or understanding your rights.

Cost Considerations

Annual Treatment Costs

Vimizim costs approximately $700,000 to $2.1 million annually depending on patient weight, with each 5mg vial costing around $1,480. Weight-based dosing means:

  • 25 kg patient: ~10 vials weekly ($770,000/year)
  • 70 kg patient: ~28 vials weekly ($2.1 million/year)

Financial Assistance Options

  • BioMarin RareConnections: Patient support program offering copay assistance and case management
  • Foundation grants: Various rare disease foundations provide financial assistance
  • State programs: New York residents may qualify for additional support through state rare disease programs

Frequently Asked Questions

How long does Humana prior authorization take in New York? Standard processing is 30 days from complete submission. Expedited reviews are available for urgent medical needs and must be completed within 72 hours.

What if Vimizim is non-formulary on my plan? Non-formulary drugs can still be covered through prior authorization based on medical necessity. The appeals process remains the same.

Can I request an expedited appeal? Yes, if delayed treatment poses serious health risks. Your physician must document the urgent medical need in the appeal request.

Does step therapy apply to Vimizim? Step therapy typically doesn't apply since Vimizim is the only FDA-approved enzyme replacement therapy for MPS IVA. However, baseline functional measures may be required.

What happens if I move to New York while on treatment? Existing patients transferring to New York must provide documentation of current clinical benefit and treatment response for continuation approval.

How often is reauthorization required? Most plans require reauthorization every 6-12 months with documentation of clinical response and continued medical necessity.

Quick Reference Checklist

Before Starting

  • Confirmed MPS IVA diagnosis with enzyme and genetic testing
  • Specialist evaluation and attestation letter
  • Baseline functional assessments completed
  • Insurance verification and PA form obtained

Documentation Package

  • Complete prior authorization form
  • GALNS enzyme activity results (below reference range)
  • Genetic testing confirming pathogenic GALNS variants
  • Specialist attestation letter with treatment rationale
  • Baseline functional test results (6-minute walk, PFTs)
  • Clinical notes documenting MPS IVA symptoms
  • Patient weight and dosing calculations

Submission

  • Submit through Humana provider portal or approved method
  • Obtain and record confirmation number
  • Schedule follow-up status check in 5-7 days
  • Prepare appeal documentation if needed

If Denied

  • Review denial letter for specific reasons
  • File internal appeal within 60 days
  • Consider external appeal through NY DFS if internal appeal unsuccessful
  • Contact Community Health Advocates for free assistance (888-614-5400)

Disclaimer: This information is for educational purposes and does not constitute medical advice. Coverage decisions depend on individual circumstances and plan terms. Always consult with your healthcare provider and insurance plan for specific guidance.

For additional support with insurance appeals and coverage decisions, Counterforce Health specializes in helping patients and providers navigate complex prior authorization requirements and turn denials into successful appeals.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.